carnitine palmitoyltransferase 2
Última actualización 17 Mar 2025
Cumple con las directrices editoriales
- DescargarDescargar
- Compartir
- Language
- Discusión
- Ask Patient
- Versión en audio
- Agregar a fuentes preferidas en Google
The CPT2 gene provides instructions for making an enzyme called carnitine palmitoyltransferase 2. This enzyme is essential for fatty acid oxidation, a multistep process that breaks down (metabolizes) fats and converts them into energy. Fatty acids are a major source of energy for the heart and muscles. During periods of fasting, fatty acids are also an important energy source for the liver and other tissues.
Selecciones de videos para GenesBiblioteca de videos
Normal function
The CPT2 gene provides instructions for making an enzyme called carnitine palmitoyltransferase 2. This enzyme is essential for fatty acid oxidation, a multistep process that breaks down (metabolizes) fats and converts them into energy. Fatty acids are a major source of energy for the heart and muscles. During periods of fasting, fatty acids are also an important energy source for the liver and other tissues.
Within liver cells, fatty acid oxidation takes place within mitochondria, which are the energy-producing centers in cells. Before they can enter mitochondria, a group of fats called long-chain fatty acids must first attach to a compound called carnitine. Once inside mitochondria, carnitine palmitoyltransferase 2 removes the carnitine from these fatty acids and adds a substance called coenzyme A. Long-chain fatty acids must be joined to coenzyme A before they can be metabolized to produce energy.
Conditions referring to this gene or chromosome
Otros nombres
CPT II
CPT2_HUMAN
CPTASE
Related patient information and medicines

Patient information leaflet
Tratamiento para la diabetes tipo 2
If you have CKD and have high levels of albumin in your urine (an albumin creatinine ratio (ACR)... Dipeptidyl. Incretins are chemicals which are produced by the gut (intestine) in response to food. Incretins: Help keep you feeling full; and Enhance your body's production of insulin; and Reduce production of another hormone, glucagon, which raises.

Patient information leaflet
Diabetes
There are two main types of diabetes - type 1 diabetes and type 2 diabetes. Find out more here: [/health/diabetes-mellitus-leaflet](https://patient.info/health/diabetes-mellitus-leaflet) Diabetes mellitus (just called diabetes from now on) occurs when the level of sugar (glucose) in the blood is higher than normal. If.

Patient information leaflet
Fiebre glandular
Glandular. Although it can make some people feel quite ill, full recovery is usual. What is glandular fever. Fiebre glandular es a viral infection, mostly caused by the Epstein-Barr virus. The virus can be passed from person to person by close contact. Glandular fever is known as infectious mononucleosis in the US and some other countries. This is.

Patient information leaflet
Diabetes tipo 2
Diabetes tipo 2 can occur at any age, including during childhood, but it occurs mainly in people aged over 40. The first-line treatment is diet, weight control and physical activity. Other treatments include reducing blood pressure if it is high, lowering high cholesterol levels, and also... This is called insulin resistance. You can learn more.

Patient information leaflet
Dieta para la diabetes tipo 2
El first-line treatment for medicamento para la diabetes tipo 2 involves making changes to your lifestyle, through diet, weight control and physical activity. Regular check-ups Type 2 diabetes and medication for diabetes (whether in tablet or injection form) definitely aren't the only way to control your blood sugar (glucose) levels. Dr Partha Kar The first-line.

Patient information leaflet
Dolor de garganta
A sore throat is common and usually goes after a few days. Simple treatments such as taking paracetamol and keeping hydrated can help ease pain. This leaflet explains the causes and treatment of sore throats. Key points A sore throat is pain or irritation in the back of the throat that is often worse when swallowing. It is usually caused by viral.
Lecturas adicionales y referencias
- carnitine palmitoyltransferase 2; MedlinePlus, National Library of Medicine.
- Corti S, Bordoni A, Ronchi D, Musumeci O, Aguennouz M, Toscano A, Lamperti C, Bresolin N, Comi GP. Clinical features and new molecular findings in Carnitine Palmitoyltransferase II (CPT II) deficiency. J Neurol Sci. 2008 Mar 15;266(1-2):97-103. doi: 10.1016/j.jns.2007.09.015. Epub 2007 Oct 23.
- Deschauer M, Wieser T, Zierz S. Muscle carnitine palmitoyltransferase II deficiency: clinical and molecular genetic features and diagnostic aspects. Arch Neurol. 2005 Jan;62(1):37-41. doi: 10.1001/archneur.62.1.37.
- Illsinger S, Lucke T, Peter M, Ruiter JP, Wanders RJ, Deschauer M, Handig I, Wuyts W, Das AM. Carnitine-palmitoyltransferase 2 deficiency: novel mutations and relevance of newborn screening. Am J Med Genet A. 2008 Nov 15;146A(22):2925-8. doi: 10.1002/ajmg.a.32545.
- Isackson PJ, Bennett MJ, Lichter-Konecki U, Willis M, Nyhan WL, Sutton VR, Tein I, Vladutiu GD. CPT2 gene mutations resulting in lethal neonatal or severe infantile carnitine palmitoyltransferase II deficiency. Mol Genet Metab. 2008 Aug;94(4):422-427. doi: 10.1016/j.ymgme.2008.05.002. Epub 2008 Jun 11.
- Joshi PR, Zierz S. Muscle Carnitine Palmitoyltransferase II (CPT II) Deficiency: A Conceptual Approach. Molecules. 2020 Apr 13;25(8):1784. doi: 10.3390/molecules25081784.
- Longo N, Amat di San Filippo C, Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet. 2006 May 15;142C(2):77-85. doi: 10.1002/ajmg.c.30087.
- LoPiccolo MK, Vockley J. Carnitine Palmitoyltransferase II Deficiency. 2004 Aug 27 [updated 2026 Apr 9]. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK1253/
- Olpin SE, Afifi A, Clark S, Manning NJ, Bonham JR, Dalton A, Leonard JV, Land JM, Andresen BS, Morris AA, Muntoni F, Turnbull D, Pourfarzam M, Rahman S, Pollitt RJ. Mutation and biochemical analysis in carnitine palmitoyltransferase type II (CPT II) deficiency. J Inherit Metab Dis. 2003;26(6):543-57. doi: 10.1023/a:1025947930752.
- Orngreen MC, Duno M, Ejstrup R, Christensen E, Schwartz M, Sacchetti M, Vissing J. Fuel utilization in subjects with carnitine palmitoyltransferase 2 gene mutations. Ann Neurol. 2005 Jan;57(1):60-6. doi: 10.1002/ana.20320.
- Ramsay RR, Zammit VA. Carnitine acyltransferases and their influence on CoA pools in health and disease. Mol Aspects Med. 2004 Oct-Dec;25(5-6):475-93. doi: 10.1016/j.mam.2004.06.002.
- Sigauke E, Rakheja D, Kitson K, Bennett MJ. Carnitine palmitoyltransferase II deficiency: a clinical, biochemical, and molecular review. Lab Invest. 2003 Nov;83(11):1543-54. doi: 10.1097/01.lab.0000098428.51765.83.
Comparte tus pensamientos o experiencias con otros en nuestro comunidades de pacientes.
Suscríbete al boletín de Patient
Tu dosis semanal de consejos de salud claros y confiables, escritos para ayudarte a sentirte informado, seguro y en control.
Al suscribirte aceptas nuestros Política de Privacidad. Puedes darte de baja en cualquier momento. Nunca vendemos tus datos.

